Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avelumab + tuvusertib
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (avelumab), Oral (tuvusertib)
01
Overview
**Avelumab + tuvusertib** is an investigational combination therapy used in clinical trials for advanced, treatment-refractory Merkel cell carcinoma. **Avelumab** is a monoclonal antibody targeting the programmed death-ligand 1 (PD-L1), functioning as a checkpoint inhibitor immunotherapy, while **tuvusertib (M1774)** is a potent, selective orally administered small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. Tuvusertib interferes with DNA repair and tumor cell replication/survival, promoting cancer cell death by inhibiting ATR kinase signaling. This combination is under study for enhancing anti-tumor immune responses and extending progression-free survival in patients resistant to prior PD-(L)1 inhibitors[1][3][5].
- Brand names
- Bavencio (avelumab)
- Other names
- avelumab + tuvusertibMATRiX regimen
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on avelumab + tuvusertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avelumab + tuvusertib.